Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

Edelson Lechtzin LLP announced that it has initiated an inquiry into whether the healthcare technology company, Semler ...

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

Q1 2026 Earnings Call Transcript June 3, 2025 HealthEquity, Inc. beats earnings expectations. Reported EPS is $0.97, ...

Humana has told congressional staffers that it will support moves that would curtail billing practices worth billions in ...

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...